血清生长分化因子15是预测MASLD患者肝癌发生的新型生物标志物且不受肝纤维化影响
在518例经活检的MASLD患者、216例验证队列及361例体检MASLD受者中,血清GDF15水平是肝癌的独立危险因素(不受纤维化分期或Fib-4指数影响)。以1.75 ng/mL为界值,高GDF15患者肝癌发生率更高,且Fib-4>1.3且高GDF15者肝癌和失代偿事件发生率显著更高、预后更差。
要点
- 血清GDF15是MASLD患者肝癌的独立危险因素,不受纤维化分期或Fib-4指数影响。
- GDF15界值1.75 ng/mL可区分肝癌高风险患者,高GDF15者肝癌发生率更高。
- Fib-4>1.3且高GDF15患者肝癌和失代偿事件发生率显著更高、预后更差。
核心结论
- 血清GDF15是预测肝癌的生物标志物,具有高预测能力,有助于识别需要定期监测的MASLD患者。
研究设计与样本
- 在518例经活检的MASLD患者、216例MASLD验证队列及361例体检MASLD受者中测量血清GDF15水平。
主要发现
- 在活检MASLD队列中,多因素分析显示血清GDF15水平是肝癌的危险因素,独立于纤维化分期或Fib-4指数。
- 以Youden指数确定的GDF15界值1.75 ng/mL,高GDF15患者不论纤维化状态如何,肝癌发生率均更高。
- Fib-4指数<1.3或低GDF15患者极少发生肝癌,而Fib-4指数>1.3且高GDF15患者肝癌和失代偿肝脏事件发生率显著更高且预后更差。
- 在验证队列中,高GDF15患者肝癌和失代偿肝脏事件发生率显著更高且预后更差,无论是否限于高Fib-4患者。
- 在体检MASLD受者中,23.0%有Fib-4指数>1.3,2.7%有Fib-4指数>1.3且GDF15>1.75 ng/mL。
关键数值与推荐
- GDF15界值为1.75 ng/mL,基于Youden指数确定。
- Fib-4指数>1.3的MASLD患者推荐进行弹性成像或活检评估纤维化。
临床怎么用
- 血清GDF15可用于识别需要定期监测的MASLD患者,尤其是Fib-4指数>1.3且高GDF15者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Although metabolic dysfunction-associated steatotic liver disease (MASLD) patients with a Fib-4 index >1.3 are recommended for fibrosis evaluation via elastography or biopsy, a more convenient method identifying high-risk populations requiring follow-up is needed. We explored the utility of serum levels of growth differentiation factor-15 (GDF15), a cell stress-responsive cytokine related to metabolic syndrome, for stratifying the risk of clinical events in MASLD patients. METHODS: Serum GDF15 levels were measured in 518 biopsy-performed MASLD patients, 216 MASLD patients for validation, and 361 health checkup recipients with MASLD. RESULTS: In the biopsy-MASLD cohort, multivariate analysis indicated that the serum GDF15 level was a risk factor for liver cancer, independent of the fibrosis stage or Fib-4 index. Using a GDF15 cutoff of 1.75 ng/mL based on the Youden index, high-GDF15 patients, regardless of fibrosis status, had a higher liver cancer incidence rate. While patients with a Fib-4 index <1.3 or low-GDF15 rarely developed liver cancer, high-GDF15 patients with a Fib-4 index >1.3 developed liver cancer and decompensated liver events at significantly higher rates and had poorer prognoses. In the validation cohort, high-GDF15 patients had significantly higher incidences of liver cancer and decompensated liver events and poorer prognoses than low-GDF15 patients, whether limited to high-Fib-4 patients. Among health checkup recipients with MASLD, 23.0% had a Fib-4 index >1.3, 2.7% had a Fib-4 index >1.3 and >1.75 ng/mL GDF15. CONCLUSIONS: Serum GDF15 is a biomarker for liver cancer with high predictive capability and is useful for identifying MASLD patients requiring regular surveillance.
引用
- Kumazaki S, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024. PMID: 38828944. doi:10.1111/apt.18063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。